Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04348838
Recruiting Observational

Prospective Cohort of Patients With Hepatocellular Carcinoma in France

NCT04348838 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2019-09-26
Last updated
2025-06-10

Condition(s) studied

Cancer of LiverHepatocellular Carcinoma

Study summary

Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities.

The CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer.

This project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * New cases of HCC * suspected case of HCC regardless of the cause, stage, treatment * Known HCC: drug treatment for recurrence or progression Exclusion Criteria: * Associated serious condition threatening life in the short term (with the exception of liver disease itself) * So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision

Primary outcome measure(s)

  • Variation of progression free survival (PFS) in intent to treat after liver transplantation — from day 1 of inclusion, up to 5 years
    Variation of progression free survival (PFS) in intent to treat after liver transplantation
  • Variation of time until failure of the strategy after hepatic resection and percutaneous destruction — from day 1 of inclusion, up to 5 years
    Variation of time until failure of the strategy after hepatic resection and percutaneous destruction
  • Variation of overall survival time (OS) after chemoembolization — from day 1 of inclusion, up to 5 years
    Variation of overall survival time (OS) after chemoembolization
  • Variation of overall survival time (OS) after radioembolization — from day 1 of inclusion, up to 5 years
    Variation of overall survival time (OS) after radioembolization
  • Variation of overall survival time (OS) after pharmaceutical treatment — from day 1 of inclusion, up to 5 years
    Variation of overall survival time (OS) after pharmaceutical treatment

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy Recruiting
MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD Recruiting
Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ? Recruiting
Salivary Replication of BK Virus in Post-kidney Transplant Starting soon
Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? Recruiting

Other trials for the same condition

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma Active, not recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma Recruiting
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer Recruiting
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04348838 on ClinicalTrials.gov ↗ ← All trials in France